SCHEMBL5864175

SCHEMBL5864175

Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(O)cc2Cl)c2ccc(CCCN3CCCC3C(=O)O)cc2)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 4/20 0.40
NR1I2 O75469 1/20 0.38
HTT P42858 2/20 0.35
POLB P06746 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CD274 Q9NZQ7 5/20 0.34
EPHX2 P34913 2/20 0.34
GAA P10253 1/20 0.34
STAT3 P40763 1/20 0.34
STAT1 P42224 1/20 0.34
STAT5B P51692 1/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
NFE2L2 Q16236 1/20 0.33
NR1H2 P55055 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863949 1.00 KEAP1 (0.40) KEAP1NR1I2HTTPOLBTSHR
SCHEMBL5864171 0.88 HRH3 (0.37) ALDH1A1
SCHEMBL5863904 0.87 DRD2 (0.38) KEAP1DRD2DRD3NFE2L2
SCHEMBL5863899 0.87 DRD2 (0.38) KEAP1DRD2DRD3NFE2L2
SCHEMBL5863928 0.85 DRD2 (0.34) KEAP1NR1I2HTTPOLBTSHR
SCHEMBL5864051 0.84 ABL1 (0.40) HSP90AA1HSP90AB1NR1H2NR1H3
SCHEMBL5864868 0.83 SIGMAR1 (0.38) HTTEPHX2GAAALDH1A1
SCHEMBL5864110 0.81 NMT1 (0.37) KEAP1ALDH1A1NFE2L2NR1H2NR1H3
SCHEMBL5864216 0.80 SIGMAR1 (0.40) KEAP1ALDH1A1NFE2L2NR1H2NR1H3
SCHEMBL5864026 0.80 KEAP1 (0.39) KEAP1NFE2L2NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053212-B2 Acyclic amide and sulfonamide ligands for the estrogen receptor PFIZER INC. (US) 2006-05-30 US claimed
EP-1542967-A1 AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR Pfizer Products Inc. (US) 2005-06-22 EP claimed
US-20040110767-A1 Acyclic amide and sulfonamide ligands for the estrogen receptor PFIZER INC 2004-06-10 US claimed
WO-2004026823-A1 AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR PFIZER PRODUCTS INC. (US) 2004-04-01 WO claimed
US-7053212-B2 Acyclic amide and sulfonamide ligands for the estrogen receptor PFIZER INC. (US) 2006-05-30 US disclosed
EP-1542967-A1 AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR Pfizer Products Inc. (US) 2005-06-22 EP disclosed
US-20040110767-A1 Acyclic amide and sulfonamide ligands for the estrogen receptor PFIZER INC 2004-06-10 US disclosed
WO-2004026823-A1 AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR PFIZER PRODUCTS INC. (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110767-A1 Acyclic amide and sulfonamide ligands for the estrogen receptor GHSR, GPER1, SSTR1 KEAP1 4082/4885NR1I2 173/4885HTT 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.